| 1 |
30365122 | Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation. | 2019 Jan |
3 |
| 2 |
28915577 | Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. | 2017 Aug 22 |
4 |
| 3 |
27382012 | Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells. | 2016 Sep |
2 |
| 4 |
25119188 | Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells. | 2015 Jan |
8 |
| 5 |
24903226 | A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. | 2014 Jul |
5 |
| 6 |
22200869 | Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. | 2012 Apr |
2 |
| 7 |
22825030 | Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. | 2012 Sep |
1 |
| 8 |
21637290 | SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. | 2011 Dec |
1 |
| 9 |
20028416 | Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. | 2010 Apr |
1 |
| 10 |
20039095 | The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. | 2010 Mar |
1 |
| 11 |
19440035 | Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cells. | 2009 Jul |
2 |
| 12 |
18342836 | Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. | 2008 May 1 |
3 |
| 13 |
17397803 | FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. | 2007 May 18 |
2 |
| 14 |
17699868 | Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. | 2007 Aug 15 |
1 |
| 15 |
15625278 | Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change. | 2005 Apr |
1 |
| 16 |
16144943 | Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | 2005 Sep 1 |
3 |
| 17 |
14679005 | Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells. | 2003 Dec 1 |
3 |